Online Forums

Our 6th annual update with EcoFact on global Regulatory and ESG policy developments. The online forum presented a deep dive into current and emerging ESG regulations that will affect our sector. Reporting requirements, due diligence regulations, climate transition planning, and nature-related risks were all part of the discussion, along with updates on emerging topics like the link between ESG and AI.

A focused group of Biopharma sustainability leaders and Biopharma sector investors convened for a direct conversation about the sector’s highest priority ESG/Sustainability topics, sparked by initial group survey results. The Workshop provided input towards our next public update of the Biopharma Investor ESG Communications Guidance.

This was an in-person event.

Harald Nusser, a seasoned healthcare executive with global experience in health equity and social business, opened our discussion about Biopharma and Human Rights with a focus on the right to health. Additional perspectives were shared by BSRT colleagues from Hikma, Organon, Pfizer, and Roche.

Jens Reissmann, Project Lead for CSRD at Bayer, shares their project strategy and experience with CSRD and Taxonomy Implementation.

Zack Pemberton-Whiteley, Exec. Director, Global Patient Engagement at Novartis, explores Patient engagement (PE) as a key topic within the ESG landscape, and its connections to long-term success.

Our 5th annual update with EcoFact on global regulatory and ESG policy developments and trends salient for the biopharma sector. The discussion focuses on topics where ESG policy and regulation is evolving rapidly and the changes will affect biopharma companies, directly or indirectly.

International Federation of Pharmaceutical Wholesalers (IFPW) — A conversation about their new ESG Framework for Healthcare. In early 2023, IFPW launched its ESG Framework for Healthcare to help create global alignment and consistency across the pharmaceutical sector on how to effectively communicate and report the impact of environmental, social, and corporate governance initiatives that advance the supply chain.

Bob Eccles, Visiting Professor of Management Practice, Saïd Business School, University of Oxford; Founding Chairman of SASB

Dennis Ostwald, CEO of the WifOR Institute, and Sonja Haut, Head Impact Valuation at Novartis, take us on a deep dive into health from the perspective of its economic impact, how Novartis is implementing impact valuation, and what this approach could mean for the Biopharma sector.